JP2014502266A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014502266A5 JP2014502266A5 JP2013540029A JP2013540029A JP2014502266A5 JP 2014502266 A5 JP2014502266 A5 JP 2014502266A5 JP 2013540029 A JP2013540029 A JP 2013540029A JP 2013540029 A JP2013540029 A JP 2013540029A JP 2014502266 A5 JP2014502266 A5 JP 2014502266A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- group
- alkyl
- aryl
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003118 aryl group Chemical group 0.000 claims 159
- 125000001072 heteroaryl group Chemical group 0.000 claims 149
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 127
- 229910052739 hydrogen Inorganic materials 0.000 claims 104
- 239000001257 hydrogen Substances 0.000 claims 101
- 125000000753 cycloalkyl group Chemical group 0.000 claims 97
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 90
- 150000002431 hydrogen Chemical class 0.000 claims 73
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 claims 63
- 229910052736 halogen Inorganic materials 0.000 claims 49
- 150000002367 halogens Chemical class 0.000 claims 48
- 125000000623 heterocyclic group Chemical group 0.000 claims 45
- 229910052757 nitrogen Inorganic materials 0.000 claims 44
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 36
- 125000003107 substituted aryl group Chemical group 0.000 claims 35
- 125000001424 substituent group Chemical group 0.000 claims 33
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 31
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 30
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 27
- 125000004093 cyano group Chemical group *C#N 0.000 claims 24
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 23
- -1 peptidyl small molecule Chemical class 0.000 claims 23
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims 22
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 22
- 239000008194 pharmaceutical composition Substances 0.000 claims 22
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 17
- 229910052799 carbon Inorganic materials 0.000 claims 17
- 125000005843 halogen group Chemical group 0.000 claims 15
- 230000003278 mimic effect Effects 0.000 claims 12
- 125000004429 atom Chemical group 0.000 claims 11
- 229910052760 oxygen Inorganic materials 0.000 claims 11
- 125000000217 alkyl group Chemical group 0.000 claims 10
- 125000005842 heteroatom Chemical group 0.000 claims 10
- 125000003545 alkoxy group Chemical group 0.000 claims 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 9
- 150000002148 esters Chemical class 0.000 claims 9
- 239000001301 oxygen Substances 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- 239000000651 prodrug Substances 0.000 claims 8
- 229940002612 prodrug Drugs 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 230000010437 erythropoiesis Effects 0.000 claims 7
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims 6
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims 6
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 6
- 125000001188 haloalkyl group Chemical group 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 101710150104 Sensory rhodopsin-1 Proteins 0.000 claims 4
- 125000001153 fluoro group Chemical group F* 0.000 claims 4
- 229910052698 phosphorus Inorganic materials 0.000 claims 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 3
- 102100034184 Macrophage scavenger receptor types I and II Human genes 0.000 claims 3
- 101710134306 Macrophage scavenger receptor types I and II Proteins 0.000 claims 3
- 125000004404 heteroalkyl group Chemical group 0.000 claims 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 208000007502 anemia Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 235000013877 carbamide Nutrition 0.000 claims 2
- 125000006850 spacer group Chemical group 0.000 claims 2
- 150000003672 ureas Chemical class 0.000 claims 2
- 230000003442 weekly effect Effects 0.000 claims 2
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 claims 1
- 208000030760 Anaemia of chronic disease Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 208000022400 anemia due to chronic disease Diseases 0.000 claims 1
- 125000002837 carbocyclic group Chemical group 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 1
- 125000004639 dihydroindenyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 claims 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 claims 1
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims 1
- 238000002638 palliative care Methods 0.000 claims 1
- 239000004031 partial agonist Substances 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 125000000547 substituted alkyl group Chemical group 0.000 claims 1
- 229940124530 sulfonamide Drugs 0.000 claims 1
- 150000003456 sulfonamides Chemical class 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 150000003556 thioamides Chemical class 0.000 claims 1
- 238000004448 titration Methods 0.000 claims 1
- 0 C*C(*C1=*C(C=CC)=*C)*(C)C1=* Chemical compound C*C(*C1=*C(C=CC)=*C)*(C)C1=* 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41527010P | 2010-11-18 | 2010-11-18 | |
| US61/415,270 | 2010-11-18 | ||
| PCT/US2011/061247 WO2012068406A2 (en) | 2010-11-18 | 2011-11-17 | Use of hematopoietic growth factor mimetics |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014502266A JP2014502266A (ja) | 2014-01-30 |
| JP2014502266A5 true JP2014502266A5 (enExample) | 2015-01-08 |
| JP6261340B2 JP6261340B2 (ja) | 2018-01-17 |
Family
ID=45217688
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013540029A Expired - Fee Related JP6261340B2 (ja) | 2010-11-18 | 2011-11-17 | 造血成長因子模倣体の使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20140243324A1 (enExample) |
| EP (1) | EP2642994A2 (enExample) |
| JP (1) | JP6261340B2 (enExample) |
| CN (1) | CN103282034A (enExample) |
| WO (1) | WO2012068406A2 (enExample) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102766135B (zh) * | 2012-07-09 | 2017-05-03 | 云南大学 | 二氢呋喃并茚烷‑咪唑盐类化合物及其制备方法 |
| HK1211589A1 (zh) | 2012-08-23 | 2016-05-27 | Alios Biopharma, Inc. | 用於治疗副粘病毒病毒性感染的化合物 |
| DK3054936T5 (da) | 2013-10-10 | 2024-03-18 | Eastern Virginia Medical School | 4-((2-hydroxy-3-methoxybenzyl)amino) benzensulfonamid derivater som 12-lipoxygenase inhibitorer |
| CA2931279A1 (en) * | 2013-11-25 | 2015-05-28 | Novogen ltd | Functionalised and substituted indoles as anti-cancer agents |
| WO2015173764A1 (en) | 2014-05-15 | 2015-11-19 | Iteos Therapeutics | Pyrrolidine-2,5-dione derivatives, pharmaceutical compositions and methods for use as ido1 inhibitors |
| KR102412146B1 (ko) | 2015-02-11 | 2022-06-22 | 주식회사 아이엔테라퓨틱스 | 소디움 채널 차단제 |
| JP6775516B2 (ja) | 2015-03-17 | 2020-10-28 | ファイザー・インク | 新奇な３−インドール置換誘導体、医薬組成物、および使用方法 |
| JP2018527336A (ja) | 2015-08-10 | 2018-09-20 | ファイザー・インク | ３−インドール置換誘導体、医薬組成物、および使用方法 |
| WO2017039318A1 (en) * | 2015-09-01 | 2017-03-09 | Kainos Medicine, Inc. | Benzimidazole derivatives for dna methylation inhibitors |
| US20170107216A1 (en) | 2015-10-19 | 2017-04-20 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| AU2016358100B2 (en) | 2015-11-19 | 2021-05-27 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| TW201726623A (zh) | 2015-12-17 | 2017-08-01 | 英塞特公司 | 作為免疫調節劑之雜環化合物 |
| TWI850624B (zh) | 2015-12-22 | 2024-08-01 | 美商英塞特公司 | 作為免疫調節劑之雜環化合物 |
| CN107176951A (zh) * | 2016-03-11 | 2017-09-19 | 恩瑞生物医药科技（上海）有限公司 | 一种脲类化合物、其制备方法及其医药用途 |
| US10844052B2 (en) | 2016-04-04 | 2020-11-24 | The Regents Of The University Of California | LLS compounds for treatment of cancer |
| TW201808950A (zh) | 2016-05-06 | 2018-03-16 | 英塞特公司 | 作為免疫調節劑之雜環化合物 |
| US20170342060A1 (en) | 2016-05-26 | 2017-11-30 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| DK3472167T3 (da) | 2016-06-20 | 2022-09-05 | Incyte Corp | Heterocykliske forbindelser som immunomodulatorer |
| EP3484866B1 (en) | 2016-07-14 | 2022-09-07 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| EP3504198B1 (en) | 2016-08-29 | 2023-01-25 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| EP3558973B1 (en) | 2016-12-22 | 2021-09-15 | Incyte Corporation | Pyridine derivatives as immunomodulators |
| ES2874756T3 (es) | 2016-12-22 | 2021-11-05 | Incyte Corp | Derivados de triazolo[1,5-A]piridina como inmunomoduladores |
| EP3558963B1 (en) | 2016-12-22 | 2022-03-23 | Incyte Corporation | Bicyclic heteroaromatic compounds as immunomodulators |
| ES2929193T3 (es) | 2016-12-22 | 2022-11-25 | Incyte Corp | Derivados de tetrahidro imidazo[4,5-c]piridina como inductores de la internalización de PD-L1 |
| IL295660A (en) | 2016-12-22 | 2022-10-01 | Incyte Corp | Benzooxazole derivatives as immunomodulators |
| WO2019100106A1 (en) * | 2017-11-24 | 2019-05-31 | The University Of Sydney | Antibacterial compounds and methods of use thereof |
| RS64055B1 (sr) | 2018-03-30 | 2023-04-28 | Incyte Corp | Heterociklična jedinjenja kao imunomodulatori |
| KR102235476B1 (ko) | 2018-03-30 | 2021-04-01 | 주식회사 엘지화학 | 액정 배향제 조성물, 이를 이용한 액정 배향막의 제조 방법, 및 이를 이용한 액정 배향막 |
| EP4219492B1 (en) | 2018-05-11 | 2024-11-27 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| GB201907558D0 (en) * | 2019-05-29 | 2019-07-10 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases |
| GB201907616D0 (en) * | 2019-05-29 | 2019-07-10 | Galapagos Nv | Novel compounds and pharmaceutical compositons thereof for the treatment of diseases |
| JP7665593B2 (ja) | 2019-08-09 | 2025-04-21 | インサイト・コーポレイション | Ｐｄ－１／ｐｄ－ｌ１阻害剤の塩 |
| EP4037773A1 (en) | 2019-09-30 | 2022-08-10 | Incyte Corporation | Pyrido[3,2-d]pyrimidine compounds as immunomodulators |
| BR112022009031A2 (pt) | 2019-11-11 | 2022-10-11 | Incyte Corp | Sais e formas cristalinas de um inibidor de pd-1/pd-l1 |
| CA3196620A1 (en) | 2020-10-05 | 2022-04-14 | Enliven Therapeutics, Inc. | 5- and 6-azaindole compounds for inhibition of bcr-abl tyrosine kinases |
| EP4240739A1 (en) | 2020-11-06 | 2023-09-13 | Incyte Corporation | Process for making a pd-1/pd-l1 inhibitor and salts and crystalline forms thereof |
| CN112321513B (zh) * | 2020-11-06 | 2022-12-23 | 药康众拓(江苏)医药科技有限公司 | 杂环类化合物及其制备方法和用途 |
| US11760756B2 (en) | 2020-11-06 | 2023-09-19 | Incyte Corporation | Crystalline form of a PD-1/PD-L1 inhibitor |
| WO2022099018A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Process of preparing a pd-1/pd-l1 inhibitor |
| JP2023552638A (ja) * | 2020-12-11 | 2023-12-18 | ティーエムイーエム１６エー リミテッド | 呼吸器疾患を治療するためのベンゾイミダゾール誘導体 |
| WO2022166482A1 (zh) * | 2021-02-04 | 2022-08-11 | 清药同创(北京)药物研发中心有限公司 | 一种苯并咪唑类enl蛋白抑制剂及其制备方法和用途 |
| KR102818206B1 (ko) * | 2021-07-12 | 2025-06-11 | 한양대학교 에리카산학협력단 | 인다졸일 벤즈이미다졸 유도체 또는 이의 약학적으로 허용가능한 염 및 이의 용도 |
| WO2023287128A1 (ko) * | 2021-07-12 | 2023-01-19 | 한양대학교 에리카산학협력단 | 인다졸일 벤즈이미다졸 유도체 또는 이의 약학적으로 허용가능한 염 및 이의 용도 |
| EP4472977A4 (en) * | 2022-02-01 | 2025-12-31 | Raadysan Biotech Inc | COMPOUNDS AND METHODS FOR CANCER INHIBITION THAT OVEREXPRESS THE C40 REPLICATION FACTOR |
| EP4479403A4 (en) * | 2022-02-18 | 2026-02-11 | Insilico Medicine Ip Ltd | MEMBRANE-ASSOCIATED TYROSINE AND THREONIN-SPECIFIC CDC2 KINASE INHIBITORS (PKMYT1) AND THEIR USES |
| EP4265247A1 (en) * | 2022-04-22 | 2023-10-25 | Université Paris Cité | Compounds inducing production of proteins by immune cells |
| EP4265246A1 (en) * | 2022-04-22 | 2023-10-25 | Université Paris Cité | Compounds inducing production of proteins by immune cells |
| WO2024077093A2 (en) * | 2022-10-04 | 2024-04-11 | University Of Rochester | Staphylococcus aureus pbp4 inhibitors and method of use |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000500464A (ja) * | 1995-11-13 | 2000-01-18 | スミスクライン・ビーチャム・コーポレイション | 血液調節化合物 |
| GB0126036D0 (en) | 2001-10-30 | 2001-12-19 | Amedis Pharm Ltd | Silicon compounds |
| WO2009155362A1 (en) * | 2008-06-19 | 2009-12-23 | Ligand Pharmaceuticals Inc. | Small molecule hematopoietic growth factor mimetic compounds and their uses |
| WO2010029300A1 (en) * | 2008-09-12 | 2010-03-18 | Biolipox Ab | Bis aromatic compounds for use in the treatment of inflammation |
| US20120004244A1 (en) * | 2009-03-12 | 2012-01-05 | Biolipox Ab | Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors |
| WO2011046954A1 (en) * | 2009-10-13 | 2011-04-21 | Ligand Pharmaceuticals Inc. | Hematopoietic growth factor mimetic small molecule compounds and their uses |
| WO2011151618A2 (en) * | 2010-06-01 | 2011-12-08 | Summit Corporation Plc | Compounds for the treatment of clostridium difficile-associated disease |
-
2011
- 2011-11-17 JP JP2013540029A patent/JP6261340B2/ja not_active Expired - Fee Related
- 2011-11-17 CN CN2011800627578A patent/CN103282034A/zh active Pending
- 2011-11-17 US US13/885,148 patent/US20140243324A1/en not_active Abandoned
- 2011-11-17 EP EP11793596.5A patent/EP2642994A2/en not_active Ceased
- 2011-11-17 WO PCT/US2011/061247 patent/WO2012068406A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014502266A5 (enExample) | ||
| JP2016506962A5 (enExample) | ||
| JP2008195730A5 (enExample) | ||
| AU2014372166B2 (en) | Pharmaceutical combinations | |
| Gao et al. | Design, synthesis and antibacterial activity evaluation of moxifloxacin-amide-1, 2, 3-triazole-isatin hybrids | |
| JP2013507446A5 (enExample) | ||
| JP2017537080A5 (enExample) | ||
| SI3009431T1 (en) | 2- (2,4,5-substituted-anilino) pyrimidine derivatives, as EGFR modulators useful for the treatment of cancer | |
| FI3406251T3 (fi) | Pyruvaattikinaasin aktivaattoreita terapeuttista käyttöä varten | |
| HRP20160725T1 (hr) | Biciklični heterociklični derivati kao inhibitori fgfr kinaze za primjenu u terapiji | |
| JP2015522650A5 (enExample) | ||
| JP2013506715A5 (enExample) | ||
| JP2016516043A5 (enExample) | ||
| JP2015501833A5 (enExample) | ||
| ME02125B (me) | Inhibitori protein apoptoze (iap) | |
| JP2014528466A5 (enExample) | ||
| HRP20192274T1 (hr) | Novi derivati oktahidro-pirolo[3,4−c]-pirola i njihovi analozi kao inhibitori autotaksina | |
| JP2016503797A5 (enExample) | ||
| JP2018507166A5 (enExample) | ||
| JPWO2012144463A1 (ja) | 腫瘍治療剤 | |
| JP2016513696A5 (enExample) | ||
| JP2017537886A5 (enExample) | ||
| SI3166925T1 (en) | Isoindoline derivatives for use in treating a viral infection | |
| JP2016540803A5 (enExample) | ||
| JP2013518036A5 (enExample) |